Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...
President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...
According to the authors, vaccine effectiveness against infection reached 44.7% (95% confidence interval [CI], 37.7% to 50.9% ...
Epidemiologist Dr. Seth Berkley spoke to Live Science about the importance of vaccine equity and the obstacles undermining it ...
The mRNA vaccines developed to fight COVID-19 during the pandemic "did have a very important impact in decreasing hospitalizations, severe pneumonia and death." ...
Mayo Clinic on MSN
COVID-19 vaccines: Get the facts
The 2025-2026 COVID-19 vaccines available in the United States include Moderna, Pfizer-BioNTech and Novavax. The vaccines are all approved for people age 65 and older. Each vaccine also is approved ...
The consensus analyst price target for Novavax stock has edged up from $12.50 to $13.21, reflecting an evolving outlook as the company navigates a transition in its business strategy. This shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback